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Background
Worsening renal function, which is associated with adverse outcomes, often develops 
in patients with acute heart failure. Experimental and clinical studies suggest that 
counterregulatory responses mediated by adenosine may be involved. We tested the 
hypothesis that the use of rolofylline, an adenosine A1−receptor antagonist, would 
improve dyspnea, reduce the risk of worsening renal function, and lead to a more 
favorable clinical course in patients with acute heart failure.
Methods
We conducted a multicenter, double-blind, placebo-controlled trial involving patients 
hospitalized for acute heart failure with impaired renal function. Within 24 hours 
after presentation, 2033 patients were randomly assigned, in a 2:1 ratio, to receive 
daily intravenous rolofylline (30 mg) or placebo for up to 3 days. The primary end 
point was treatment success, treatment failure, or no change in the patient’s clinical 
condition; this end point was defined according to survival, heart-failure status, 
and changes in renal function. Secondary end points were the post-treatment devel-
opment of persistent renal impairment and the 60-day rate of death or readmission 
for cardiovascular or renal causes.
Results
Rolofylline, as compared with placebo, did not provide a benefit with respect to the 
primary end point (odds ratio, 0.92; 95% confidence interval, 0.78 to 1.09; P = 0.35). 
Persistent renal impairment developed in 15.0% of patients in the rolofylline group 
and in 13.7% of patients in the placebo group (P = 0.44). By 60 days, death or readmis-
sion for cardiovascular or renal causes had occurred in similar proportions of pa-
tients assigned to rolofylline and placebo (30.7% and 31.9%, respectively; P = 0.86). 
Adverse-event rates were similar overall; however, only patients in the rolofylline 
group had seizures, a known potential adverse effect of A1-receptor antagonists.
Conclusions
Rolofylline did not have a favorable effect with respect to the primary clinical com-
posite end point, nor did it improve renal function or 60-day outcomes. It does not 
show promise in the treatment of acute heart failure with renal dysfunction. (Funded 
by NovaCardia, a subsidiary of Merck; ClinicalTrials.gov numbers, NCT00328692 
and NCT00354458.)
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Preexisting chronic kidney disease and worsening renal function are common in patients hospitalized with acute heart 
failure and are associated with poor outcomes.1-5 
Multiple factors are responsible for this associ-
ation,3-5 including coexisting conditions, less 
use of effective therapies in patients with renal 
dysfunction than in patients without renal dys-
function, and inadequate treatment of volume 
overload because of a suboptimal response to 
diuretics or concern regarding diuretic toxicity.4,5
Adenosine has been implicated as an impor-
tant intrarenal mediator of both worsening renal 
function and diuretic resistance.6,7 ATP hydroly-
sis releases free adenosine into the extracellular 
space, which in turn acts on adenosine A1 recep-
tors in the afferent arterioles, reducing renal 
blood flow and the glomerular filtration rate 
(GFR) and stimulating the release of renal renin. 
In addition, A1-receptor activation enhances prox-
imal tubular sodium reabsorption.6,7 In patients 
with heart failure, A1-receptor antagonists may 
preserve the GFR, enhance sodium excretion, 
and improve diuretic responsiveness.
Previous studies involving patients with heart 
failure have shown that coadministration of A1-
receptor antagonists and loop diuretics enhances 
diuresis while maintaining or improving renal 
function.8-10 In the PROTECT (Placebo-Controlled 
Randomized Study of the Selective A1 Adenosine 
Receptor Antagonist Rolofylline for Patients Hos-
pitalized with Acute Decompensated Heart Fail-
ure and Volume Overload to Assess Treatment 
Effect on Congestion and Renal Function) pilot 
study, a dose-finding study,11 rolofylline at a dose 
of 10, 20, or 30 mg or placebo was administered 
daily for up to 3 days in patients with acute heart 
failure, underlying renal dysfunction, and volume 
overload. As compared with patients who re-
ceived placebo, patients who received the 30-mg 
dose of rolofylline had greater relief of dyspnea 
and less worsening of renal function, with a trend 
toward fewer deaths or readmissions for heart or 
renal failure. The present phase 3 PROTECT trial 
was designed to confirm these findings.12
Me thods
Study Design and Oversight
This randomized, double-blind trial compared 
rolofylline with placebo in patients hospitalized 
for acute heart failure at 173 sites in North Amer-
ica, Europe, Israel, and Argentina. The study, 
which was sponsored by NovaCardia, a subsidiary 
of Merck, was designed by an executive commit-
tee consisting of seven investigators and two 
Merck clinical scientists and was based largely 
on the design and results of the pilot study.11 The 
background, design, and results of the pilot 
study, as well as a summary of the design and 
protocol modifications that were made for the 
phase 3 study, are included in the Supplementary 
Appendix, available with the full text of this ar-
ticle at NEJM.org. The protocol was approved by 
the ethics committee at each participating center, 
and patients provided written informed consent.
The study was monitored by an independent 
data and safety monitoring committee, which 
was supported by an independent statistical cen-
ter with a staff that was aware of the study-drug 
assignments (Statistics Collaborative). The only 
stopping rule for efficacy was a reduction in 
180-day mortality crossing an O’Brien−Fleming 
boundary that preserved an overall (one-sided) 
false positive error rate of 0.005.13 Hospitaliza-
tions, central nervous system events, and deaths 
within 60 days after study-drug administration 
were adjudicated by an independent clinical events 
committee that was unaware of treatment assign-
ments. The site investigators gathered the primary 
data, which was monitored by an independent 
contract research organization (Averion Interna-
tional, formerly Hesperion). Statistical analyses 
were performed by Averion with the use of SAS 
software, version 8.2 (SAS Institute), and these 
analyses were subsequently confirmed by Merck. 
The executive committee had full access to the 
final data set. The first author prepared the ini-
tial draft of the manuscript, which was revised 
on the basis of the comments of the other au-
thors, who each approved the final version. All 
authors vouch for the accuracy and completeness 
of the reported data as well as the fidelity of the 
reported results to the trial protocol.
Study Patients
Eligibility criteria included persistent dyspnea at 
rest or with minimal activity, impaired renal 
function (an estimated creatinine clearance of 
20 to 80 ml per minute with the use of the 
Cockcroft−Gault equation), a brain natriuretic 
peptide level of 500 pg per milliliter or more or 
an N-terminal pro-brain natriuretic peptide level 
of 2000 pg per milliliter or more, ongoing intra-
venous loop-diuretic therapy, and enrollment 
within 24 hours after admission. Other inclusion 
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and exclusion criteria have been described previ-
ously12 and are included in the Supplementary 
Appendix.
Since adenosine A1−receptor antagonists may 
lower the threshold for seizures in predisposed 
patients, those with a history of seizures or pre-
disposing factors for seizures were excluded.12 
Patients with a more distant history of condi-
tions or factors associated with a lower seizure 
risk were pretreated with 1 mg of oral lorazepam 
or clonazepam 30 minutes before administration 
of the study drug. The criteria used to define a 
low seizure risk are available in the Supplemen-
tary Appendix.
Study Procedures
Thirty milligrams (0.5 mg per milliliter) of rolofyl-
line (NovaCardia) or matching placebo was ad-
ministered as a 4-hour intravenous infusion daily 
for up to 3 days in a double-blind manner ac-
cording to a computer-generated randomization 
scheme (in a 2:1 ratio of rolofylline to placebo), 
assigned through a central randomization system.
Symptoms and signs of heart failure were 
evaluated before the initial administration of the 
study drug, daily through discharge or day 6, 
and on days 7 and 14. Patients reported symp-
toms of change in their breathing and their 
general well-being with the use of a 7-point Likert 
scale of change relative to baseline (ranging from 
−3 to 3, with higher scores indicating greater 
improvement). Moderately or markedly improved 
dyspnea was defined as a score of either 2 or 3 on 
this scale. Measurements of the serum creatinine 
level were recorded at the same time points.14,15 
Worsening heart failure in the period from study-
drug initiation through day 7 was reported on 
the basis of worsening signs or symptoms lead-
ing to intensification of therapy.
Study End Points
The primary end point was treatment success, 
treatment failure, or no change in the patient’s 
condition. Success was defined as patient-reported 
moderate or marked improvement in dyspnea 
both 24 and 48 hours after administration of the 
study drug, in the absence of any criterion for 
failure. Failure was defined as the occurrence of 
any of the following: death or readmission for 
heart failure through day 7, worsening symptoms 
and signs of heart failure occurring more than 24 
hours after the initiation of the study drug re-
quiring intervention by day 7 or discharge (if 
earlier), or persistent worsening renal function, 
defined as an increase in the serum creatinine 
level of 0.3 mg per deciliter (26.5 µmol per liter) 
or more from randomization to day 7, confirmed 
at day 14, or the initiation of hemofiltration or 
dialysis during the period from initiation of the 
study drug through day 7. Patients were classified 
as having unchanged treatment status if they met 
neither the criteria for treatment success nor the 
criteria for treatment failure.
Two secondary outcomes were prespecified: 
death from any cause or rehospitalization for 
cardiovascular or renal causes through day 60 
and the proportion of patients with persistent 
renal impairment, defined as an increase in the 
serum creatinine level of 0.3 mg per deciliter or 
more by day 7, confirmed at day 14; the initia-
tion of hemofiltration or dialysis through day 7; 
or death by day 7.
Adverse events were recorded through day 7, and 
serious adverse events were recorded through 
day 14; they were classified according to the 
Medical Dictionary for Regulatory Activities. Safe-
ty was evaluated on the basis of the incidence of 
adverse events and laboratory abnormalities. The 
seriousness of adverse events and their related-
ness to the study drug were determined by the 
investigators. Patients or family members were 
contacted by telephone to identify deaths and 
readmissions up to day 60 and to assess vital 
status at day 180. Patients who were hospitalized 
were asked about the reason for readmission.
Statistical Analysis
PROTECT was initially planned as two identical 
600-patient studies to be conducted simultane-
ously (PROTECT-1 and PROTECT-2; ClinicalTrials 
.gov numbers, NCT00328692 and NCT00354458, 
respectively). In this article, the combined trials 
are referred to as PROTECT. The first patient was 
enrolled in May 2007, and in December 2007, the 
protocol was amended to specify a combined 
analysis of the two studies and an increase in 
sample size from 1200 to 2000 patients to main-
tain 90% power with a more stringent definition 
of significance.
Efficacy end points were evaluated in the in-
tention-to-treat population. The effectiveness of 
rolofylline with respect to the primary end point 
was evaluated in the combined studies at a sig-
nificance level of 0.00125. The planned sample 
of 2000 patients provided approximately 90% 
power to detect a difference between a distribu-
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tion of 25% failure, 34% no change, and 41% 
success in the rolofylline group and a distribu-
tion of 33% failure, 35% no change, and 32% 
success in the placebo group with the use of the 
Wilcoxon test.
If the primary end point was achieved, both 
secondary end points were to be tested at a nomi-
nal two-sided significance level of 0.05. The study 
design provided 95% power at the two-sided sig-
nificance level of 0.05 to detect a hazard ratio of 
0.74 for death or rehospitalization for cardiovas-
cular or renal causes and a 33% relative reduc-
tion in the rate of persistent renal impairment 
with the use of a Cochran−Mantel−Haenszel test.
The study groups were compared with respect 
to the primary end point with the use of the van 
Elteren extension of the Wilcoxon test,16 strati-
fied according to study and geographic region of 
Table 1. Baseline Characteristics of the Patients and Use of Concomitant Therapies in the Intention-to-Treat 
Population.*
Variable
Rolofylline 
(N = 1356)
Placebo
(N = 677) P Value†
Demographic characteristics
Age (yr) 70.2±11.7 70.2±11.5 0.94
Sex (%) 0.82
Male 67.3 66.8
Female 32.7 33.2
Race (%)‡ 0.73
White 95.2 95.5
Other 4.8 4.5
Measurements
Body-mass index§ 28.9±6.1 28.8±6.2 0.65
Blood pressure (mm Hg)
Systolic 124.3±17.6 124.2±17.7 0.85
Diastolic 73.6±11.8 74.0±11.9 0.47
Heart rate at rest in the supine position (beats/min) 79.8±15.3 80.7±15.7 0.22
Respiratory rate (breaths/min) 21.2±4.5 21.3±4.4 0.50
BNP (pg/ml)¶ 0.62
Median 1290 1198
Interquartile range 833−2222 773−2235
NT-proBNP (pg/ml)¶ 0.85
Median 3000 3000
Interquartile range 3000−3832 3000−3800
Creatinine clearance (ml/min) 50.4±20.0 51.0±20.5 0.55
Left ventricular ejection fraction within previous 6 mo‖ 0.323±0.129 0.325±0.135 0.76
Medical history (%)
Heart failure 1 mo before admission 94.6 95.1 0.63
Ischemic heart disease 70.5 68.5 0.36
Myocardial infarction 50.8 46.3 0.06
Hypertension 80.2 77.8 0.21
Atrial fibrillation 53.5 57.0 0.14
Implantable cardioverter−defibrillator 16.2 15.5 0.69
Biventricular pacemaker 10.5 9.8 0.63
Diabetes 45.2 45.8 0.79
COPD or asthma 20.0 19.4 0.75
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enrollment (region 1 consisted of North America, 
Western Europe, and Israel, and region 2 con-
sisted of Central Europe, Eastern Europe, and 
Argentina). The odds ratio and 95% confidence 
interval for the treatment effect were determined 
from an ordered logistic-regression (proportional-
odds) model that included terms for the effects 
of treatment, study, and geographic region. Given 
the classification (−1 denoting failure, 0 no 
change, and 1 success), an odds ratio of less 
than 1.0 would favor active treatment.
For the end point of time to death from any 
cause or rehospitalization for cardiovascular or 
renal causes through day 60, the treatment groups 
were compared with the use of a Cox regression 
model, stratified according to study and geo-
graphic region. Cumulative event rates were cal-
culated with the use of the Kaplan−Meier method. 
Table 1. (Continued.)
Variable
Rolofylline 
(N = 1356)
Placebo
(N = 677) P Value†
Treatment before admission (%)
ACE inhibitor or ARB 76.3 74.4 0.36
Beta-blocker 76.5 75.7 0.71
Aldosterone blocker 44.5 42.4 0.36
Nitrates (oral or topical) 27.0 23.9 0.13
Digoxin 27.3 29.6 0.27
Treatment after admission
Days of study-drug administration (%)** 0.60
1 day 7.6 7.0
2 or 3 days 90.9 91.6
Medications through day 7
Total intravenous loop diuretic (mg) 0.07
Median 280 280
Interquartile range 120−545 140−620
Intravenous inotropes or vasopressors (%) 7.2 8.0 0.54
Intravenous vasodilators (%) 11.3 11.5 0.87
Medications at discharge or day 7, if earlier (%)
ACE inhibitor or ARB 82.6 81.5 0.50
Beta-blocker 84.6 84.2 0.84
Aldosterone blocker 59.8 60.3 0.81
Nitrates (oral or topical) 21.0 19.1 0.33
Digoxin 31.8 34.6 0.21
*  Plus−minus values are means ±SD. ACE denotes angiotensin-converting enzyme, ARB angiotensin-receptor blocker, 
BNP brain natriuretic peptide, COPD chronic obstructive pulmonary disease, and NT-proBNP N-terminal pro-BNP.
†  The P values for comparisons of mean values between the two groups are from a two-sample t-test. Medians are 
based on the Wilcoxon test (except for the total milligrams of intravenous loop diuretics, which are based on the van 
Elteren extension of the Wilcoxon test). The P values for comparisons of percentages are based on the chi-square test.
‡  Race was self-reported.
§  The body-mass index is the weight in kilograms divided by the square of the height in meters.
¶  Either a BNP level of 500 pg per milliliter or more or an NT-proBNP level of 2000 pg per milliliter or more was re-
quired for enrollment. A point-of-care device for measuring the level of NT-proBNP was provided to study sites if 
needed, but measurements of more than 3000 pg per milliliter were not quantified, which explains the median values 
of 3000 pg per milliliter. The BNP level was measured in 537 patients, and the NT-proBNP level was measured in 
1518 patients.
‖  The ejection fraction was reported if it was available within 6 months before admission. Data were available for 975 
patients.
** Percentages in this category do not sum to 100 because the data were not available in 1.5% and 1.6% of patients in 
the rolofylline and placebo groups, respectively.
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The proportion of subjects with persistent re-
nal impairment was analyzed with the use of a 
Cochran−Mantel−Haenszel test, stratified accord-
ing to study and geographic region.
For the primary end point and the two second-
ary end points, the treatment effect was evaluated 
across 11 prespecified baseline subgroups accord-
ing to the study (PROTECT-1 or PROTECT-2), geo-
graphic region, sex, age (≤70 years or >70 years), 
race (white or other), ethnic group (Hispanic or 
Latino, or other), pretreatment or no pretreatment 
with a benzodiazepine, left ventricular ejection 
fraction (<40% or ≥40%), baseline serum creati-
nine level (less than the median or greater than or 
equal to the median), severity of heart failure 
(New York Heart Association class I or II, III, 
or IV), and baseline creatinine clearance (<30, 30 to 
<60, 60 to <80, or ≥80 ml per minute).
R esult s
Patients
Between May 2007 and January 2009, a total of 
2033 patients were randomly assigned to a study 
drug (1356 to rolofylline and 677 to placebo). Of 
these patients, 21 who were assigned to the 
rolofylline group and 10 who were assigned to 
the placebo group did not receive the study drug 
and were excluded from safety analyses. Ran-
domization of the patients, treatment, and out-
comes are shown in Figure 1 in the Supple-
mentary Appendix. Only 1 patient was lost to 
follow-up at the 60-day assessment; vital status at 
180 days could not be ascertained for 5 patients.
Important demographic, clinical, and treat-
ment characteristics of the patients are shown in 
Table 1. The study groups were well matched 
with respect to all baseline variables. Most pa-
tients had chronic heart failure before admis-
sion, ischemic heart disease, and one or more 
additional coexisting conditions. The mean crea-
tinine clearance was 51 ml per minute, and levels 
of natriuretic peptides were substantially elevated.
More than 90% of patients received two or 
three doses of the study drug. The median doses 
of intravenous loop diuretics (in furosemide dose 
equivalents) administered from randomization 
through day 7 or discharge, if earlier, were 280 mg 
(interquartile range, 120 to 545) in the rolofyl-
line group and 280 mg (interquartile range, 140 
to 620) in the placebo group (P = 0.07). The high-
est quartile of diuretic doses was substantially 
higher in the placebo group than in the rolofyl-
line group. Weight loss during the first 4 days 
was greater with the use of rolofylline (3.0 vs. 
2.6 kg, P = 0.005). Additional intravenous vasoac-
tive agents were administered before day 7 in 17% 
of the patients in the rolofylline group and 16% 
of the patients in the placebo group.
Primary Efficacy End Points
Rolofylline, as compared with placebo, was not 
beneficial with respect to the primary end point 
(the proportions of patients in whom treatment 
was successful, treatment failed, or there was no 
change in the patient’s condition), yielding an 
odds ratio of 0.92 (95% confidence interval [CI], 
0.78 to 1.09; P = 0.35) (Fig. 1 and Table 2). More 
patients in the rolofylline group than in the pla-
cebo group met the criteria for treatment success 
(40.6% vs. 36.0%; odds ratio, 1.22; 95% CI, 1.01 to 
1.47; P = 0.04). However, the proportion of treat-
ment failures was also higher in the rolofylline 
group than in the placebo group (21.8% vs. 19.8%; 
odds ratio, 1.13; 95% CI, 0.90 to 1.42; P = 0.30), 
reflecting a numerical excess of patients who 
met the criteria for worsening renal function 
(12.7% vs. 11.1%, P = 0.31). Other criteria for 
treatment failure were similar in the rolofylline 
and placebo groups, including early death (in 
1.7% and 2.1% of patients in the two groups, 
respectively), early worsening heart failure (9.1% 
and 9.7%), and rates of early readmission for 
heart failure (0.4% and 0.6%). There was no clear 
evidence of heterogeneity in outcome among the 
prespecified subgroups or in post hoc analyses 
involving patients with or without diabetes or 
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Figure 1. Distribution of the Primary Composite End Point in the Rolofylline 
and Placebo Groups.
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diuretic doses above or below the median (Fig. 2A 
in the Supplementary Appendix).
Secondary Efficacy End Points
Through day 60, a total of 386 of 1356 patients 
assigned to rolofylline (Kaplan–Meier estimate, 
30.7%; 95% CI, 27.8 to 33.6) as compared with 
195 of 677 patients assigned to placebo (Kaplan–
Meier estimate, 31.9%; 95% CI, 27.4 to 36.4) died 
or were readmitted for cardiovascular or renal 
causes (hazard ratio, 0.98; 95% CI, 0.83 to 1.17; 
P = 0.86) (Fig. 2). Persistent renal impairment oc-
curred in 15.0% of the patients in the rolofylline 
group as compared with 13.7% of the patients in 
the placebo group (odds ratio, 1.11; 95% CI, 0.85 
to 1.46; P = 0.44). These results were generally con-
sistent across subgroups (Fig. 2 in the Supplemen-
tary Appendix). Rates of death over a period of 
180 days were similar (17.9% in the rolofylline 
group and 17.4% in the placebo group; hazard 
ratio, 1.03; 95% CI, 0.82 to 1.28; P = 0.82) (Fig. 3).
Safety
At least one adverse event was reported in 840 of 
1336 patients treated with rolofylline (62.9%) and 
in 409 of 666 patients who received placebo 
(61.4%). In the rolofylline group, 185 patients had 
serious adverse events (13.8%) as compared with 
98 patients in the placebo group (14.7%). These 
serious adverse events led to discontinuation of 
the study drug in 1.5% of the patients in each 
group; they were associated with a fatal outcome 
in 3.7% of the patients in the rolofylline group 
and 5.3% of the patients in the placebo group. 
Most serious adverse events were cardiac events; 
these were reported in 96 patients who received 
rolofylline (7.2%) and 60 patients who received 
placebo (9.0%). The rates of the two most fre-
quent serious cardiac events, worsening heart 
failure and ventricular tachycardia, both tended 
to be lower among patients who received rolofyl-
line (P = 0.04 and P = 0.10, respectively).
Imbalances were observed with respect to the 
investigator-reported neurologic adverse events. 
By day 14, a total of 11 patients in the rolofylline 
group (0.8%), but no patients in the placebo group, 
had seizures (risk difference, 0.8 percentage points; 
95% CI, 0.3 to 1.5; P = 0.02), of whom only 1 had 
received pretreatment with a benzodiazepine. Fif-
teen patients who received rolofylline (1.1%) and 
Table 2. Odds Ratios for the Primary Composite End Point in the Intention-to-Treat Population.
Variable
Rolofylline 
(N = 1356)
Placebo 
(N = 677) Odds Ratio (95% CI) P Value
number (percent)
Outcome 0.92 (0.78−1.09)* 0.35†
Treatment success 551 (40.6) 244 (36.0) 1.22 (1.01−1.47)‡ 0.04‡
No change in patient’s condition 509 (37.5) 299 (44.2)
Treatment failure 296 (21.8) 134 (19.8) 1.13 (0.90−1.42)‡ 0.30‡
Criterion for treatment failure§
Death during the first 7 days 23 (1.7) 14 (2.1)
Readmission for heart failure during the first 7 days 5 (0.4) 4 (0.6)
Worsening heart failure, days 3–7 123 (9.1) 66 (9.7)
Persistent worsening of renal function during the first 
7 days
172 (12.7) 75 (11.1)
* The analysis was based on a proportional-odds model that included terms for the effect of treatment, the study, and 
the geographic region.
† The analysis was performed with the use of the van Elteren extension of the Wilcoxon test, stratified according to the 
study and geographic region.
‡ The analysis was performed with the use of the Cochran−Mantel−Haenszel test, stratified according to the study and 
geographic region. An odds ratio of less than 1 favors rolofylline for the primary end point, and an odds ratio of more 
than 1 favors rolofylline for the treatment-success component of the primary end point and placebo for the treatment-
failure component of the primary end point.
§ Percentages for each criterion for treatment failure are based on the total number of patients in each study group. The 
total percentage exceeds the percentage of patients with treatment failures, since some patients met more than one 
 criterion. These analyses were not prespecified and are provided for informational purposes only. None of the compari-
sons achieved nominal statistical significance.
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2 patients who received placebo (0.3%) had strokes 
(risk difference, 0.8 percentage points; 95% CI, 
0.0 to 1.6; P = 0.06). There was no particular pat-
tern of stroke events in the rolofylline group 
with regard to the stroke type (5 were hemor-
rhagic, 6 were ischemic, 3 were embolic, and 1 
was a spinal cord infarction) or the temporal 
relationship to administration of the study drug 
(10 occurred within 6 days after the last dose 
and 5 occurred ≥7 days after the last dose) (Ta-
ble 1 in the Supplementary Appendix).
Discussion
The clinical and economic burdens of heart fail-
ure have been well described.17 Treatment ad-
vances over the past 25 years have improved 
symptoms and quality of life and increased sur-
vival among patients with chronic heart failure.18 
In contrast, although approximately one third of 
patients with acute heart failure die or are re-
admitted within 3 months after discharge,19-21 
new therapies have consistently failed to improve 
their outcomes.20 Patients with underlying chron-
ic kidney disease or worsening renal function are 
at particularly high risk.1,2,4,5,22,23
As a result, there has been considerable inter-
est in A1-receptor antagonists, which have en-
hanced the response to diuretics in patients with 
heart failure, usually without further deteriora-
tion of renal function.7-10,23-25 With the use of a 
protocol that was similar to that in the present 
trial, the PROTECT pilot study randomly assigned 
301 patients with acute heart failure to placebo 
or to 10-, 20-, or 30-mg doses of rolofylline.11 In 
the pilot trial, the group of patients who received 
30 mg of rolofylline were more likely than those 
who received placebo to have improvement in 
dyspnea on days 2 and 3 (59.4% of patients vs. 
41.3%) and were less likely to have persistent 
renal impairment (8.0% vs. 18.2%), with a trend 
toward a lower 60-day rate of death or readmis-
sion for cardiovascular or renal causes (19% vs. 
34%; hazard ratio, 0.55; 95% CI, 0.28 to 1.04; 
P = 0.06).
However, despite similarities in study design, 
entry criteria, and dose of rolofylline, the main 
trial reported here did not replicate the findings 
of the pilot trial. Several reasons for this discor-
dance warrant consideration. The protocol under-
went several revisions. First, one of the inclusion 
criteria for the current trial, but not for the pilot 
trial, was an increased level of brain natriuretic 
peptide or N-terminal pro-brain natriuretic pep-
tide; nonetheless, nearly 80% of the patients in 
the pilot trial would have qualified for the pres-
ent trial. Second, the criterion for successful 
treatment was changed from a physician-direct-
ed switch from intravenous to oral diuretics to 
patient-reported improvement in symptoms. None-
theless, rolofylline was associated with a signifi-
cantly higher rate of success than placebo. Finally, 
on the basis of the data from the pilot study and 
regulatory input, the definition of persistent renal 
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Patients or their family members were contacted by telephone between days 
55 and 65, so events that occurred in this interval are included in this analysis.
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impairment was changed from an increase in 
the serum creatinine level of 0.3 mg per deciliter 
or more from baseline to discharge or day 7 to 
an increase at both day 7 and day 14. The neutral 
results of PROTECT primarily reflect this lack of 
a favorable effect on the serum creatinine level.
Perhaps the most likely explanation for the dif-
ferences between the findings in the two studies 
is the large uncertainty about the results of the 
pilot study because of the small treatment groups 
and the dependence on these findings in design-
ing critical elements of the main trial, including 
the selection of a single dose, entry criteria, and 
end points.11 The post hoc selection of the best of 
three dose groups from a pilot trial with multiple 
small treatment groups carries the inherent risk 
that an apparent superiority may be the play of 
chance and that these findings may not be repli-
cable in a more definitive, larger study, as hap-
pened in the current trial. These findings should 
encourage the conduct of larger phase 2 studies 
with more robust, clinically relevant end points.
A total of 0.8% of the patients who received 
rolofylline (as compared with none who received 
placebo) had seizures, a recognized risk of agents 
with A1 receptor−antagonist activity because of 
their tendency to lower the threshold for sei-
zures.26,27 The excess of strokes in the rolofylline 
group was unanticipated, is difficult to interpret, 
and is not clearly explained by the pharmaco-
logic characteristics of the drug.
In conclusion, the primary and secondary end 
points were not achieved with rolofylline in the 
current trial. The current trial and previous un-
successful trials of treatment for acute heart fail-
ure highlight the complexity and heterogeneity 
of this clinical syndrome and the need for new, 
more effective therapeutic approaches.
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